Blood vessel cells help tumors evade the immune system

A new study is the first to suggest that cells in the tumor blood vessels contribute to a local environment that protects the cancer cells from tumor-killing immune cells. The results can contribute to the development of better immune-based cancer therapies.
Source: ScienceDaily Headlines - Category: Science Source Type: news

Related Links:

Roche already owns a majority stake in Foundation Medicine, but now the Swiss company wants to buy the rest of the genomic diagnostics company, and it is willing to pay a pretty penny to do so. Roche agreed to pay $137 a share to buy the rest of Cambridge, MA-based Foundation Medicine, a $2.4 billion transaction that values the company at $5.3 billion. The offer price represents a 29% premium over Foundation Medicine's closing stock price Monday. The deal is expected to close during the second half of the year. The deal marks a turning point in Roche's relationship with Foundation Medicine, which dates back to January...
Source: MDDI - Category: Medical Devices Authors: Tags: Business Source Type: news
By CHARLES SILVER and DAVID A.HYMAN Today THCB is happy to publish a piece reflecting the learnings from Charles Silver and David Hyman’s forthcoming book Overcharged: Why Americans Pay Too Much For Health Care, shortly to be published by the libertarian leaning Cato Institute. In subsequent weeks we’ll feature commentary from the right (Michael Cannon) and from the left (Andy Slavitt) about the book and its proposals. For now please give your views in the comments–Matthew Holt There are many reasons why the United States is “the most expensive place in the world to get sick.” In Par...
Source: The Health Care Blog - Category: Consumer Health News Authors: Tags: Economics OP-ED Cato Institute Charles Silver David A. Hyman Obamacare Overcharged Source Type: blogs
by Sung-Young Shin, Anna-Katharina M üller, Nandini Verma, Sima Lev, Lan K. Nguyen Prediction of drug combinations that effectively target cancer cells is a critical challenge for cancer therapy, in particular for triple-negative breast cancer (TNBC), a highly aggressive breast cancer subtype with no effective targeted treatment. As signalling pathway networks critically control cancer cell behaviour, analysis of signalling network activity and crosstalk can help predict potent drug combinations and rational stratification of patients, thus bringing therapeutic and prognostic values. We have previously showed that th...
Source: PLoS Computational Biology - Category: Biology Authors: Source Type: research
AbstractPurpose of reviewWith the continuing development of newer targeted therapies in oncology, it is necessary to understand their potential cardiovascular side effects. In this review, we discuss the association of novel targeted agents and left ventricular systolic dysfunction.Recent findingsWithin the last 5  years, multiple new agents have been developed to target specific cancer pathways and found to have off-targeted cardiotoxicity. The most recent example is the recognition of myocarditis caused by immune checkpoint inhibitors.SummaryThe development of targeted cancer therapies has revolutionized oncology, b...
Source: Current Treatment Options in Cardiovascular Medicine - Category: Cardiology Source Type: research
AbstractPurpose of reviewAs cancer survivor rates improve with early screening and modern treatment options, cardiotoxicity is becoming an increasing problem. It is imperative for physicians to recognize adverse events early so that appropriate measures can be taken before advanced and permanent cardiac dysfunction ensues. In this review, we will evaluate the literature surrounding current cardiac biomarkers in the detection of cardiotoxicity during cancer treatment as well as discuss the role of emerging novel biomarkers.Recent findingsTroponin and brain natriuretic peptides show promise in the detection of subclinical ca...
Source: Current Treatment Options in Cardiovascular Medicine - Category: Cardiology Source Type: research
Elekta (STO:EKTA B) said today it won CE Mark approval in the European Union for its Elekta Unity magnetic resonance radiation therapy system. The Stockholm-based company touted that its Unity system allows clinicians to deliver radiation doses while simultaneously visualizing the tumor and surrounding tissue through MR imaging. The system also features integrated advanced tools that allow the operator to adapt treatment based on anatomical information. “Unity is a tremendous innovation in patient care, one that enables a scan-plan-treat approach to developing tailored regimens that should yield substantive clinical ...
Source: Mass Device - Category: Medical Devices Authors: Tags: Imaging Oncology Regulatory/Compliance Elekta Source Type: news
Baltimore biotechnology firm WindMIL Therapeutics has raised a $32.5 million to support clinical trials and further development for new cancer therapies. The Series B round was led by QiMing USA Venture Partners, the new U.S. entity of China firm QiMing. WindMIL, a cell therapy company, is previously backed by about $11 million in funding. WindMIL was founded out of Johns Hopkins University by researchers Kimberly Noonan and Dr. Ivan Borrello. Th e clinical stage company is working to develop…
Source: bizjournals.com Health Care:Physician Practices headlines - Category: American Health Authors: Source Type: news
In this study, p53 wildtype (LoVo) and human p53 mutated (HT29 and SW480) colorectal cancer cells were treated with the miniFlatPlaSter - a device particularly developed for the treatment of tumor cells - that uses the Surface Micro Discharge (SMD) technology for plasma production in air. The present study analyzed the effects of plasma on colorectal cancer cells in vitro and on normal colon tissue ex vivo. Plasma treatment had strong effects on colon cancer cells, such as inhibition of cell proliferation, induction of cell death, and modulation of p21 expression. In contrast, CAP treatment of murine colon tissue ex vivo f...
Source: Biological Chemistry - Category: Chemistry Tags: Biol Chem Source Type: research
AbstractImmune checkpoint antagonists (CTLA-4 and PD-1/PD-L1) and CAR T-cell therapies generate unparalleled durable responses in several cancers and have firmly established immunotherapy as a new pillar of cancer therapy. To extend the impact of immunotherapy to more patients and a broader range of cancers, targeting additional mechanisms of tumor immune evasion will be critical. Adenosine signaling has emerged as a key metabolic pathway that regulates tumor immunity. Adenosine is an immunosuppressive metabolite produced at high levels within the tumor microenvironment. Hypoxia, high cell turnover, and expression of CD39 ...
Source: Journal for Immunotherapy of Cancer - Category: Cancer & Oncology Source Type: research
This study sought to develop a simple nanoparticle-based approach to enhance the efficiency and tolerability of lipopolysaccharide (LPS), a potent ligand of Toll-like Receptor 4 (TLR4), for immunotherapy in cancer. Despite holding promise within this context, the strong pro-inflammatory properties of LPS also account for its low tolerability given localized and systemic side effects, which restrict the administrable dosage. Herein, we investigated the effect of LPS decoration as a surface-active molecule on a polymeric matrix upon its efficiency and tolerability. The LPS-decorated nanoparticles (LPS-NP) were about 150&thin...
Source: Drug Delivery - Category: Drugs & Pharmacology Tags: Drug Deliv Source Type: research
More News: Cancer | Cancer & Oncology | Cancer Therapy | Environmental Health | Science | Study